 |
First Clinical Data Presented with IMGN853, ImmunoGen, Inc.'s Potential New Therapy for Ovarian and Other Cancers
Jun 3, 2013
|
72.6 KB |
| |
First clinical findings presented with ImmunoGen's folate receptor
α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853.
Preliminary evidence of activity seen in dose-finding portion of
trial.
WALTHAM, Mass.--(BUSINESS WIRE)--
Immuno...
|
|
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
May 30, 2013
|
6.0 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) antibody-drug conjugate (ADC) technology, today
announced that the following presentations by Company management at
upcoming i...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conference
May 3, 2013
|
5.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
antibody-drug conjugate (ADC) technology, today announced that Gregory
Perry, Executive Vice President and Chief Financial Officer, wil...
|
|
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Apr 26, 2013
|
58.7 KB |
| |
First product with ImmunoGen's ADC technology, Kadcyla™, launched
in the US. Multiple additional markets, indications expected.
Three novel wholly owned ImmunoGen compounds advancing in clinical
testing, with the first clinical data for IMGN853 to be reported at
ASCO. Preclinical...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2013 Financial Results
Apr 18, 2013
|
5.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer therapeutics, today announced that the Company will host a
conference call at 8:00 a.m. ET on Friday, April 26, 2013, to discuss
ImmunoGen's financial results for the three-month pe...
|
|
Webcast of the ImmunoGen, Inc. Analyst and Investor Community Meeting on April 12, 2013
Apr 11, 2013
|
5.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics, today announced that investors, journalists and
the general public are invited to listen to a live webcast of the
Company's analyst and investor community meeting on April ...
|
|
ImmunoGen, Inc. Announces Preclinical Findings with its IMGN289 Product Candidate for the Treatment of EGFR-Overexpressing Cancers
Apr 10, 2013
|
11.4 KB |
| |
Novel antibody-drug conjugate (ADC) can kill Epidermal Growth
Factor Receptor (EGFR)-overexpressing cancer cells via two mechanisms
— EGFR-inhibition and direct cell-killing.
In preclinical testing, IMGN289 was highly active against
EGFR-overexpressing cancer cells, including tho...
|
|
ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Community Meeting on April 12, 2013
Mar 12, 2013
|
5.5 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics, today announced that investors, journalists and
the general public are invited to listen to a live webcast of the
Company's analyst and investor community meeting on April 12, ...
|
|
ImmunoGen, Inc. Announces FDA Approval of Kadcyla (Ado-Trastuzumab Emtansine; Also Known as T-DM1)
Feb 22, 2013
|
9.5 KB |
| |
Product demonstrates the power of ImmunoGen's Targeted Antibody
Payload (TAP) technology — first antibody-drug conjugate approved for
a solid tumor indication.
Compound to be marketed in the US by Genentech, a member of the Roche
Group, under the brand name Kadcyla™; was pr...
|
|
ImmunoGen, Inc. Attains Patient Enrollment Milestone in IMGN901 NORTH Trial
Feb 12, 2013
|
9.3 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops targeted anticancer therapeutics, today announced
that it has completed patient enrollment in the first stage of its NORTH
two-stage Phase II trial. The NORTH trial is assessing the Company's
...
|
|
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
Feb 5, 2013
|
6.3 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that the following
presentations by Company management at upcoming investor conferen...
|
|
ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update
Jan 25, 2013
|
57.3 KB |
| |
Trastuzumab emtansine (T-DM1) marketing applications are under
review in the US and Europe; US application has priority review status
with a PDUFA date of February 26, 2013.
In 2013, ImmunoGen expects to report clinical findings with its
three lead wholly owned compounds and to advance...
|
|
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2013 Financial Results
Jan 18, 2013
|
5.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology
company that develops anticancer products using its Targeted Antibody
Payload (TAP) technology and antibody expertise, today announced that
the Company will host a conference call at 8:00 a.m. ET on Friday,
January...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the 31st Annual J.P. Morgan Healthcare Conference
Jan 2, 2013
|
5.7 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that Daniel Junius,
President and CEO, will present at the upcoming 31st Annual
...
|
|
Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology
Dec 19, 2012
|
5.4 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and antibody expertise, today
announced that Amgen has licensed the exclusive right to use the
Company's maytansino...
|
|
ImmunoGen, Inc. Announces IMGN901 Clinical Data Presented at ASH
Dec 10, 2012
|
9.6 KB |
| |
Benefit seen in both lenalidomide-naïve and lenalidomide-refractory
multiple myeloma
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and...
|
|
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 23rd Annual Healthcare Conference
Dec 6, 2012
|
5.6 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therapeutics using its Targeted Antibody Payload (TAP)
technology and antibody expertise, today announced that Daniel Junius,
President and CEO, will present at the upcoming Oppenheimer 23rd...
|
|
ImmunoGen, Inc. Announces Clinical Data Presentations at the 54th ASH Annual Meeting and Exposition
Dec 3, 2012
|
8.1 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops anticancer therapeutics using its Targeted
Antibody Payload (TAP) technology and antibody expertise, today
announced that there will be clinical data presentations on two
compounds that utiliz...
|
|
ImmunoGen, Inc. Appoints Dr. Charles Morris as Chief Development Officer
Nov 26, 2012
|
8.4 KB |
| |
— Dr. Morris brings to the Company extensive experience
leading the successful development and registration of novel anticancer
compounds —
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops
anticancer therape...
|
|
ImmunoGen, Inc. Announces FDA Has Granted Priority Review Status to the Trastuzumab Emtansine (T-DM1) Marketing Application
Nov 6, 2012
|
5.9 KB |
| |
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a
biopharmaceutical company that develops anticancer products using its
Targeted Antibody Payload (TAP) technology and antibody expertise, today
announced that Genentech, a member of the Roche Group, has disclosed
that the U.S. Fo...
|
|
|
